Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Apr 17;105(8):526-35.
doi: 10.1093/jnci/djt043. Epub 2013 Mar 29.

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study

Rowan T Chlebowski  1 , JoAnn E Manson, Garnet L Anderson, Jane A Cauley, Aaron K Aragaki, Marcia L Stefanick, Dorothy S Lane, Karen C Johnson, Jean Wactawski-Wende, Chu Chen, Lihong Qi, Shagufta Yasmeen, Polly A Newcomb, Ross L Prentice
Affiliations
Multicenter Study

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study

Rowan T Chlebowski et al. J Natl Cancer Inst. .

Abstract

Background: In the Women's Health Initiative (WHI) randomized trial, estrogen plus progestin increased both breast cancer incidence and mortality. In contrast, most observational studies associate estrogen plus progestin with favorable prognosis breast cancers. To address differences, a cohort of WHI observational study participants with characteristics similar to the WHI clinical trial was studied.

Methods: We identified 41 449 postmenopausal women with no prior hysterectomy and mammogram negative within 2 years who were either not hormone users (n = 25 328) or estrogen and progestin users (n = 16 121). Multivariable-adjusted Cox proportional hazard regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CI). All statistical tests were two-sided.

Results: After a mean of 11.3 (SD = 3.1) years, with 2236 breast cancers, incidence was higher in estrogen plus progestin users than in nonusers (0.60% vs 0.42%, annualized rate, respectively; HR = 1.55, 95% CI = 1.41 to 1.70, P < .001). Women initiating hormone therapy closer to menopause had higher breast cancer risk with linear diminishing influence as time from menopause increased (P < .001). Survival after breast cancer, measured from diagnosis, was similar in combined hormone therapy users and nonusers (HR = 1.03, 95% CI = 0.79 to 1.35). On a population basis, there were somewhat more deaths from breast cancer, measured from cohort entry (HR = 1.32, 95% CI = 0.90 to 1.93, P = .15), and more all-cause deaths after breast cancer (HR = 1.65, 95% CI = 1.29 to 2.12, P < .001) in estrogen plus progestin users than in nonusers.

Conclusions: Consistent with WHI randomized trial findings, estrogen plus progestin use is associated with increased breast cancer incidence. Because prognosis after diagnosis on combined hormone therapy is similar to that of nonusers, increased breast cancer mortality can be expected.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Invasive breast cancer incidence by estrogen plus progestin use at baseline. Analyses were adjusted for age, race or ethnic group, body mass index, education, smoking status, alcohol use, self-reported health, level of physical activity, presence or absence of a family history of breast cancer, estimated breast-cancer risk based on the Gail model, and bilateral oophorectomy and stratified by baseline age group. All statistical tests were two-sided. CI = confidence interval; HR = hazard ratio.
Figure 2.
Figure 2.
Invasive breast cancer incidence by estrogen plus progestin use at baseline modified by time-from-menopause to hormone therapy initiation (gap time). Nonparametric spline fit for the hazard ratio (HR) (95% confidence interval [CI] in shaded region) of the effect of estrogen plus progestin by gap time. The smoothness of the fit was chosen objectively by generalized cross-validation. P values corresponds to a test of whether the effect of estrogen plus progestin changes with gap time. Analyses were adjusted for age, race or ethnic group, body mass index, education, smoking status, alcohol use, self-reported health, level of physical activity, presence or absence of a family history of breast cancer, estimated breast-cancer risk based on the Gail model, and bilateral oophorectomy and stratified by baseline age group. All statistical tests were two-sided.
Figure 3.
Figure 3.
Survival after breast cancer diagnosis by estrogen plus progestin use at baseline. Analyses were adjusted for age, race or ethnic group, body mass index, education, smoking status, alcohol use, self-reported health, level of physical activity, presence or absence of a family history of breast cancer, estimated breast-cancer risk based on the Gail model, bilateral oophorectomy, and age at diagnosis and stratified by baseline age group. All statistical tests were two-sided. CI = confidence interval; HR = hazard ratio.
Figure 4.
Figure 4.
Breast cancer mortality by estrogen plus progestin use at baseline. Panels depict (A) deaths from breast cancer (deaths directly attributed to the cancer) and (B) deaths after breast cancer (deaths from all causes after the cancer). Analyses were adjusted for age, race or ethnic group, body mass index, education, smoking status, alcohol use, self-reported health, level of physical activity, presence or absence of a family history of breast cancer, estimated breast-cancer risk based on the Gail model, and bilateral oophorectomy. All statistical tests were two-sided. CI = confidence interval; HR = hazard ratio.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

  • Classical and Non-Classical Progesterone Signaling in Breast Cancers.
    Pedroza DA, Subramani R, Lakshmanaswamy R. Pedroza DA, et al. Cancers (Basel). 2020 Aug 27;12(9):2440. doi: 10.3390/cancers12092440. Cancers (Basel). 2020. PMID: 32867363 Free PMC article. Review.
  • Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database.
    Wu J, Liu H, Hu T, Wang S. Wu J, et al. Hereditas. 2022 Mar 22;159(1):18. doi: 10.1186/s41065-022-00230-3. Hereditas. 2022. PMID: 35317849 Free PMC article.
  • Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium.
    Morra A, Jung AY, Behrens S, Keeman R, Ahearn TU, Anton-Culver H, Arndt V, Augustinsson A, Auvinen PK, Beane Freeman LE, Becher H, Beckmann MW, Blomqvist C, Bojesen SE, Bolla MK, Brenner H, Briceno I, Brucker SY, Camp NJ, Campa D, Canzian F, Castelao JE, Chanock SJ, Choi JY, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Egan KM, Evans DG, Fasching PA, Flyger H, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Giles GG, Grip M, Guénel P, Haiman CA, Håkansson N, Hall P, Hamann U, Han SN, Hart SN, Hartman M, Heyworth JS, Hoppe R, Hopper JL, Hunter DJ, Ito H, Jager A, Jakimovska M, Jakubowska A, Janni W, Kaaks R, Kang D, Kapoor PM, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Lacey JV, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lubiński J, Lush M, Mannermaa A, Manoochehri M, Margolin S, Mariapun S, Matsuo K, Mavroudis D, Milne RL, Muranen TA, Newman WG, Noh DY, Nordestgaard BG, Obi N, Olshan AF, Olsson H, Park-Simon TW, Petridis C, Pharoah PDP, Plaseska-Karanfilska D, Presneau N, Rashid MU, Rennert G, Rennert HS, Rhenius V, Romero A, Saloustros E, Sawyer EJ, Schneeweiss A, Schwentner L, Scott C, Shah M, Shen CY, Shu XO… See abstract for full author list ➔ Morra A, et al. Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):623-642. doi: 10.1158/1055-9965.EPI-20-0924. Epub 2021 Jan 26. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 33500318 Free PMC article.
  • Botanicals and Their Bioactive Phytochemicals for Women's Health.
    Dietz BM, Hajirahimkhan A, Dunlap TL, Bolton JL. Dietz BM, et al. Pharmacol Rev. 2016 Oct;68(4):1026-1073. doi: 10.1124/pr.115.010843. Pharmacol Rev. 2016. PMID: 27677719 Free PMC article. Review.
  • Screening for Chemical Contributions to Breast Cancer Risk: A Case Study for Chemical Safety Evaluation.
    Schwarzman MR, Ackerman JM, Dairkee SH, Fenton SE, Johnson D, Navarro KM, Osborne G, Rudel RA, Solomon GM, Zeise L, Janssen S. Schwarzman MR, et al. Environ Health Perspect. 2015 Dec;123(12):1255-64. doi: 10.1289/ehp.1408337. Epub 2015 Jun 2. Environ Health Perspect. 2015. PMID: 26032647 Free PMC article. Review.
See all "Cited by" articles

References

    1. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA. 2003; 289(24):3243–3253 - PubMed
    1. Chlebowski RT, Anderson GL. Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst. 2012; 104(7):1–11 - PMC - PubMed
    1. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010; 304(15):1684–1692 - PMC - PubMed
    1. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995; 332(24):1589–1593 - PubMed
    1. Bergkvist L, Adami HO, Persson J, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol. 1989; 130(2):221–228 - PubMed

Publication types

MeSH terms